8H9 131I
As of the edition of 20 October 2026, 8H9 131I is a drug: stopped in 2009; acts on CD276.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2009
- Kind
- Unknown
- Registered trials
- 1, 1 stopped early
- Disease areas
- Cancer; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD276 | CD276 antigen | Q5ZPR3 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| All trials | 1 |